BRPI0518105A - uso de antagonista da angiogênese e uso de anticorpo anti-vegf - Google Patents

uso de antagonista da angiogênese e uso de anticorpo anti-vegf

Info

Publication number
BRPI0518105A
BRPI0518105A BRPI0518105-4A BRPI0518105A BRPI0518105A BR PI0518105 A BRPI0518105 A BR PI0518105A BR PI0518105 A BRPI0518105 A BR PI0518105A BR PI0518105 A BRPI0518105 A BR PI0518105A
Authority
BR
Brazil
Prior art keywords
vegf antibody
angiogenesis
treatment
angiogenesis antagonist
antagonists
Prior art date
Application number
BRPI0518105-4A
Other languages
English (en)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0518105A publication Critical patent/BRPI0518105A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE ANTAGONISTA DA ANGIOGêNESE E USO DE ANTICORPO ANTI-VEGF. O presente pedido descreve terapia com antagonistas da angiogênese, tais como anticorpo anti-VEGF. Particularmente, a presente invenção descreve o uso desses antagonistas para o tratamento de doenças autoimunes em pacientes que fracassaram em tratamento anterior taI como tratamento com DMARDs ou inibidores de TNF<244>.
BRPI0518105-4A 2004-12-17 2005-12-16 uso de antagonista da angiogênese e uso de anticorpo anti-vegf BRPI0518105A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17
PCT/US2005/045600 WO2006066086A1 (en) 2004-12-17 2005-12-16 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Publications (1)

Publication Number Publication Date
BRPI0518105A true BRPI0518105A (pt) 2008-11-04

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518105-4A BRPI0518105A (pt) 2004-12-17 2005-12-16 uso de antagonista da angiogênese e uso de anticorpo anti-vegf

Country Status (23)

Country Link
US (2) US20060134111A1 (pt)
EP (1) EP1824885A1 (pt)
JP (1) JP2008524241A (pt)
KR (1) KR20070086218A (pt)
CN (1) CN101120020A (pt)
AR (1) AR052056A1 (pt)
AU (1) AU2005316403A1 (pt)
BR (1) BRPI0518105A (pt)
CA (1) CA2587932A1 (pt)
CR (1) CR9181A (pt)
IL (1) IL183347A0 (pt)
MA (1) MA29366B1 (pt)
MX (1) MX2007007165A (pt)
NO (1) NO20073651L (pt)
NZ (1) NZ555286A (pt)
PE (1) PE20061075A1 (pt)
RU (1) RU2007126970A (pt)
SG (1) SG158089A1 (pt)
SV (1) SV2006002342A (pt)
TN (1) TNSN07191A1 (pt)
TW (1) TW200634026A (pt)
WO (1) WO2006066086A1 (pt)
ZA (1) ZA200704898B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043312B (en) * 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
ATE470454T1 (de) 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010054221A2 (en) * 2008-11-06 2010-05-14 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
HUE065752T2 (hu) * 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2706358A3 (en) * 2008-12-23 2014-05-07 Merck Patent GmbH Biomarkers for inhibitors with anti-angiogenic activity
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
RU2016142476A (ru) * 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
ES2622983T3 (es) * 2015-02-11 2017-07-10 Deutsches Krebsforschungszentrum Terapia contra el cáncer con un parvovirus combinado con bevacizumab
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
IL183347A0 (en) 2007-09-20
AR052056A1 (es) 2007-02-28
ZA200704898B (en) 2009-03-25
MX2007007165A (es) 2007-08-14
CN101120020A (zh) 2008-02-06
US20060134111A1 (en) 2006-06-22
AU2005316403A1 (en) 2006-06-22
SV2006002342A (es) 2006-06-01
WO2006066086A1 (en) 2006-06-22
TNSN07191A1 (en) 2008-11-21
TW200634026A (en) 2006-10-01
CA2587932A1 (en) 2006-06-22
NZ555286A (en) 2010-04-30
CR9181A (es) 2008-07-31
KR20070086218A (ko) 2007-08-27
RU2007126970A (ru) 2009-01-27
PE20061075A1 (es) 2006-11-15
MA29366B1 (fr) 2008-04-01
EP1824885A1 (en) 2007-08-29
SG158089A1 (en) 2010-01-29
JP2008524241A (ja) 2008-07-10
NO20073651L (no) 2007-09-10
US20080214789A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
BRPI0518105A (pt) uso de antagonista da angiogênese e uso de anticorpo anti-vegf
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
BRPI0514666A (pt) antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BRPI0409534A (pt) métodos para o tratamento de doença autoimune e de artrite reumatóide, método de redução do risco de efeito colateral negativo, usos de um antagonista que se liga a um marcador de superfìcie de células b e uso de um anticorpo que se liga a cd20
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
JO2576B1 (en) Antibodies
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
BRPI0410986A (pt) derivados de estaurosporina para sìndrome hipereosinofìlica
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
WO2004073649A3 (en) Clk-peptide and slk-peptide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.